info@auctorespublishing.com
+1-(302)-520-2644
+1-(302)-520-2644

Tregs and Other Suppressive/Regulatory/Tolerogenic Cell Therapies in Transplantation

  1. Home
  2. Journals
  3. Cancer Research and Cellular Therapeutics
  4. Archives
Submit Guidelines

Review Article | DOI: https://doi.org/10.31579/2640-1053/066

Tregs and Other Suppressive/Regulatory/Tolerogenic Cell Therapies in Transplantation

  • Muñoz-Sánchez G 1
  • Betriu S 1
  • González-Navarro E.A 1,2
  • Ortiz de Landázuri I 1
  • González-Navarro E.A 1,2
  • Esteve-Solé A 3
  • San Bartolomé C 1
  • Egri N 1
  • Palou E 1
  • Juan M 1,2,3

1 Servei d’Immunologia, Hospital Clínic de Barcelona, ​​University of Barcelona, ​​Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Barcelona, Spain.
1,2 Platform d’Immunoteràpia Hospital Sant Joan de Déu- Clínic. Platform d’Immunoteràpia Banc de Sang I Teixits-Clínic. Barcelona, ​​Spain.
3 Functional Unit of Clinical Immunology, Sant Joan de Déu-Hospital Clinic, Barcelona, ​​Spain.

*Corresponding Author: Manel Juan, Servei d’Immunologia, Hospital Clínic de Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August. Barcelona, Spain

Citation: Muñoz-Sánchez G , Betriu S, Esteve-Solé A.3, Ortiz de Landázuri I, González-Navarro E.A, Español-Rego M, San Bartolomé C, Egri N, Palou E, Juan M. Tregs and Other Suppressive/Regulatory/Tolerogenic Cell Therapies in Transplantation, J. Cancer Research and Cellular Therapeutics. Doi: 10.31579/2640-1053/066

Copyright: © 2020 Manel Juan, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,provided the original author and source are credited.

Received: 30 December 2019 | Accepted: 06 January 2020 | Published: 07 January 2020

Keywords: treg; transplantation; rejection; cell therapy

Abstract

Poor long-term graft outcome remains problematic because of the inability to prevent chronic allograft rejection. Strategies based on suppression/regulation/tolerance (3 different but similarly used concepts) of the immune system often leads to other concerns. New alternatives based on facilitating the induction of alloantigen tolerance by regulatory T cells (Tregs) and other immune-suppressor cells can restore the balance between inhibitory and effector arm. This review mainly summarizes results about the use of Tregs for the control of transplant rejection, commenting also other situations and potentially similar cell therapies.

Introduction

Poor long-term graft outcome remains problematic because of the inability to prevent chronic allograft rejection. Strategies based on suppression/regulation/tolerance (3 different but similarly used concepts) of the immune system often leads to other concerns. New alternatives based on facilitating the induction of alloantigen tolerance by regulatory T cells (Tregs) and other immune-suppressor cells can restore the balance between inhibitory and effector arm. This review mainly summarizes results about the use of Tregs for the control of transplant rejection, commenting also other situations and potentially similar cell therapies.

Organ transplantation is currently a successful treatment for the majority of patients with end-stage organ failure. Fortunately, improvement in transplant technology, non-invasive biomarkers, better selection of donors and recipients by Human Leukocyte Antigen (HLA) typing/compatibility and the advance of immunosuppresive agents have enabled clear progress in transplantation outcomes ameliorating the graft survival, at least in the early post-transplant stage. However, the poor long-term graft outcome remains problematic because of the inability to prevent chronic allograft rejection (CR). In fact, half of all transplanted kidneys still fail within 15 years after transplantation[1]. In this context, the current treatment of transplantation focuses on the limitation of the effector arm of immune response with nonspecific immunosuppressive drugs (ISD) that perform by inhibiting non-specific T and B cell activation pathways or by depleting lymphocytes.

The mentioned strategy based on suppression of the immune system often leads to over immunosuppression. The lack of specificity of ISD frequently diminishes patient’s quality of life and gives rise to life-threatening infection episodes, malignancies, cardiovascular diseases or kidney failure causing graft loss or even death [2]. Due to the inconveniences caused in transplanted patients by this therapeutic approach, new alternatives that allow better results are being sought. In general, suppression, regulation or tolerance induction are different terms that often are interchangeably used. Although “Suppressor” cells suggest the blockage of responses, “Regulatory” should be a more flexible concept (increase or decrease functions) but just used under the meaning of suppression, and “Tolerogenic” cells are those cells that could induce specific recognition which would program no-response, the three concepts are often used as synonymous. Facilitating the induction of alloantigen tolerance by regulatory T cells (Tregs) and other immune-suppressor cells, restoring the balance between the inhibitory and the effector arm is the aim of a lot of novel strategies based on suppressive/regulatory/tolerogenic cells. Although this review mainly summarizes results about the use of Tregs as controllers of rejection in transplantation, other situations and potential similar cell therapies are also commented.

Fig 1. Mechanisms of action of suppressor/regulatory/tolerogenic cells.

Tregs: Regulatory T-cells; MSCs: Mesenchymal stromal cells; MMP: matrix metalloproteinase; Mregs: regulatory macrophages; MDSCs myeloid-derived suppressor cells; iNOs: inducible NO synthase; Tol-DCs: Tolerogenic DCs; Bregs: Regulatory B cells; CAR-Tregs: Treg cells expressing chimeric antigen receptor. Tregs induce apoptosis of alloreactive T cells via CTLA-4 and PD-1 engagement. 

Besides, Tregs prevent APC’s ability to activate effector T cells by CTLA-4 and LAG-3 binding. Other mechanisms such as TGF-β expression, inducible cAMP early repressor (ICER), IL-10 and miRNA exosome transference are also involved. MSCs secrete MMP types 2 and 9 facilitating the cleavage of CD25 expressed on CD4+ T cells. Both Mregs and MDSCs have immunossupressive activity in an iNOS-dependent pathway. Tol-DCs are able to induce Treg development via CD80/86, ICOS-L, ILT3, ILT4 and PD-L1 binding. Bregs can modulate immune homeostasis in an IL-10 dependent pathway or by IL-10-independent mechanisms based on IL-35 or TGF-β

 . CAR-Tregs recognize specific antigens such as HLA-A2 supressing allograft rejection.

1. - General concepts about Tregs

1.1. Characterization and Ontogeny

Tregs are a subset of CD4+ T cells (comprising 1-9% of blood CD4+ T cells) whose function is to limit immune responses by maintaining self-tolerance. Tregs are traditionally classified as natural Tregs (thymus-derived), or peripheral inducible Tregs (iTregs), which are the result of natural T-cells when exposed to cytokines such as TGF-β and IL-2p[3,4]. Tregs are distinguished by the high expression of both CD4+ and CD25+ (IL-2 alpha chain Receptor) and by the transcriptional regulator Forkhead Box P3 (FOXP3)[5], which is a reliable marker specially in mouse Tregs. However, FOXP3 is also expressed in human effector T cells when activated[6] and it is required the use of other markers such as CD4+/CD25+/CD127- to characterize them. Additionally, transcription factor FOXP3 demethylation serves to preserve Treg phenotype and related epigenetic changes are now used to identify Tregs in clinical research [7].

Thymic ontogeny of Tregs starts in CD4 single-positive stage (CD4+/CD8-). Upregulation of FOXP3 and consequent differentiation of Tregs depends on a great heterogeneity of paths and cytokines ruled by environmental conditions and is strongly influenced by inflammatory cues. Antigen Presenting Cells (APCs) in thymus promote FOXP3 upregulation in these thymocytes by self-antigen-presenting in the context of self-MHC class II8. This event together with a satisfactory interaction with CD28 in terms of strength, duration and affinity[9] activates nuclear factor-κB (NF-κB), forkhead box protein O (FOXO) and nuclear factor of activated T cells (NFAT)[10], which is required for FOXP3 expression. 

Other factors, like the presence of high concentrations of TGF-β[11], Inducible Costimulator (ICOS/ICOSL) and thymic stromal lymphopoietin are also involved[12]. Also, FOXP3 upregulation event promotes Interleukin-2 receptor alpha chain (also called CD25) surface expression allowing cytokine signalling and consequently the development of fully functional Tregs [13]. 

1.2. Immunosuppressive drugs and Tregs

PI3K-mTOR (mammalian target of rapamycin) signalling pathway is recognized as one of the main targets of ISD used in transplantation. mTOR is a critical signalling molecule with a crucial role in transcribing immunological cues into a specific family of T cells. Extensive studies at the molecular level of this pathway are imperative for unravelling Tregs association with immunosuppresive drugs, cancer and autoimmunity.

 How mTOR regulates Treg phenotype and metabolism is not fully understood. mTOR is formed by two complexes named mTOR1(Raptor), the principal target of rapamycin (RAPA), and mTOR2 (Rictor). T cells lacking whole mTOR complex differentiate preferentially into FOXP3+ Treg rather than Th1, Th2 or Th17 effector cells [14] and expand more efficiently in the presence of IL-2 compared with normal-mTOR T cells. It has been suggested that TGF-β mediated induction of Foxp3+ regulatory cells in deficient mTOR T-cells could explain this divergence given that Tregs development is regulated by a protein named Smad3, which is more likely to be stimulated by TGF-β in mTOR-deficient Treg cells. However, mice containing Treg specific deletion of Raptor (mTOR1) lose their Treg function in vivo [15] and develop fatal autoimmune inflammatory state [16].

Many immunosuppressive drugs currently used base their mechanism on the mTOR pathway determining Tregs function and transplantation outcome. For instance, calcineurin inhibitors have shown a negative effect on Tregs generation and function [17] while there is substantial evidence that rapamycin favours Treg survival and function [18]. The effects of mycophenolic acid are variable [19,20] and regarding basiliximab, due to its anti-CD25 effect, may have a deleterious effect on Treg cells [21]. Nonetheless, either via mTOR or by another alternative mechanism there is a widespread observation that the percentage of circulating CD25+ CD4+ FOXP3 cells decreases after transplantation [22]. This way, the balance between immunoreactive and immunosuppressive status gets compromised concluding in the adverse events or reactions described above. That is the main reason why new approaches focusing on tolerance induction via Tregs or other promising methods such as regulatory macrophages or mixed chimerism should be considered.

2. - Tregs in transplantation

As regulatory T cells are essential for the induction and preservation of peripheral tolerance and hence for preventing graft rejection, they have been deeply studied and seriously taken into consideration as a new therapeutic tool. Data suggest that Tregs could exert a tolerant state to alloantigens in vivo by inducing a regulatory profile in alloreactive T cells. Before describing the therapeutic approaches by which we could take profit of Tregs, it is convenient to describe briefly the main steps where Tregs get involved suppressing allorejection to understand the multiple pathways that could be affected by manipulating these cells.

In the setting of any solid organ transplantation, donor APCs migrate to the lymph nodes and present allogeneic class I or class II MHC molecules to the recipient’s CD8+ and CD4+ T cells, respectively (direct presentation). Host dendritic cells can also display and present graft alloantigens to T lymphocytes (indirect presentation) resulting in naive T cells differentiation and proliferation into effector helper T cells and cytotoxic T lymphocytes. These effector T cells migrate back into the graft and mediate cellular rejection. The usefulness of Tregs resides in their capability of regulating this rejection process in different ways.

Tregs are able to induce cytotoxic T lymphocyte apoptosis via engagement of CTLA-4 (cytotoxic T lymphocyte antigen-4) and PD1 (Programmed cell death 1), granzyme A/B, TNF related apoptosis-inducing ligand (TRAIL), FAS/FAS-ligand pathway, the galectin/TIM-3 pathway and through IL-2 deprivation. On the other hand, Treg’s CTLA-4 binds with CD80/86 on APCs leading to the induction of indolamine-2,3-dioxygenase (IDO)[23,24] and LAG-3 binds with MHC-II preventing APC’s ability to activate effector T cells[25]. Other mechanisms mediated by Tregs as TGF-β membrane-bound active expression, upregulation of ICER (inducible cAMP early repressor)[26] and the consequent inhibition of NFAT and IL-2 transcription by cAMP transference from Tregs to effector T cells, IL-10/IL-35/TGF-β production and miRNA exosome[27] transference are also suppressive physiological cues focused on diminishing immune response and rejection.

3. - T-immunotherapies (from Tregs to CARTregs)

Diverse therapies based on the use of immune-related cells to induce tolerance are currently undergoing clinical trials. Tolerance induction could be advantageous in different circumstances such as autoimmunity, in which control of self-reactive lymphocytes is defective, or transplantation. Even though Tregs are the cornerstone of this review, other cell strains are being considered and studied as tolerance inductors like myeloid-derived suppressor cells (MSDC), Mesenchymal Stem Cells (MSC), regulatory macrophages (Mreg), tolerogenic Dendritic Cells (Tol-DCs) or regulatory B lymphocytes (Breg).

3.1. Polyclonal Treg cells

Polyclonal Treg cells are non-antigen-specific cells (in contrast with antigen-specific Tregs we will describe later). Regulatory T cells are a well-defined subset that can be cultivated and expanded ex vivo and returned safely to patients. The low rate of Tregs in adults (less than 9% of CD4+) requires their expansion ex vivo before clinical use. Polyclonal expansion generates large numbers of Tregs from peripheral blood with potential use as adoptive cell therapy. First of all, cells can be sourced directly from the patient (autologous) or a third-party unrelated donor (allogeneic). The source of autologous Treg cells is limiting and current manufacturing conditions are demanding and costly. On the other hand, allogeneic Tregs offer exceptional opportunities when immune host-mediated elimination of transferred cells is overcome, allowing a durable response.

In terms of production and isolation, the best marker to characterize Treg cells is a nuclear transcription factor (FOXP3) and therefore is not suitable for isolation by flow cytometry since it is an intracellular complex. As described above, CD25 is highly expressed in most Treg cells but is transiently shared with effector T cells, so cannot be used by itself to avoid unwanted T-cells [28].

In the present day, there are different protocols for regulatory Treg production. One option is to use CD8, CD14, CD19 and CD127 negative selection to discard non-CD4 T-cells followed by CD25 positive selection[28]. Instead of selection, Treg induction protocol is based on FOXP3 expression promoters (IL-2, TGF-β activation and use of mTOR inhibitors). By using mentioned promoters together with TCR activation we could selectively stimulate Treg development[28]. Once we have selected/induced Treg subset, expansion and proliferation is required; IL-2 is used as a growth factor promoting expansion and survival of Tregs previously isolated [29].

Clinical trials to determine the safety and stability of this cell therapy have been carried out. In solid organ transplantation, the ONE study (NCT02129881) has shown that Treg cells can be grown and are safe for administration to transplant recipients in a dose-escalating approach from 0.5-3.0x106 cells/kg. There is an attractive argument for combining Treg with rapamycin (RAPA) monotherapy, since rapamycin may facilitate the survival of Tregs. Starting from ONE study, the so-called TWO study (MR/N027930/1), which started in 2017 and will end in 2023, aims to elucidate if nTreg can actually control rejection. For this purpose, 34 renal transplant recipients will be recruited over three years and each receptor will be treated with conventional immunosuppressive drugs. However, after transplant, cellular therapy of Treg isolated from their own blood (autologous) will be administered. Then, the immunosuppressive drug dose will be reduced while renal function monitoring is carried out. Thus, evidence of nTreg role in protecting grafts from damage could be tested[30].

3.2 Antigen-specific Treg therapies

Efficacy of antigen-specific Tregs should be higher than polyclonal Tregs [31,32] but their expansion is challenging due to low precursor rates. Some studies suggest that these alloantigen-expanded Tregs are 100-fold more potent at suppressing alloantigen-stimulated proliferation in vitro than polyclonal Tregs [33]. Different approaches to obtain antigen-specific Tregs should be taken into account: 1) purified antigen-specific Tregs; 2) specific TCR transduction; 3) CAR Tregs, in which the CAR (Chimeric Antigen Receptor) recognizes specific targets; and 4) specific effector T cells reconverted into Treg cells by FOXP3 overexpression.

1. Purified antigen-specific Tregs

The frequency of direct allo-reactive Tregs (darTregs) has been estimated to be between 1% and 10% [33]. Proof-of-principle researches have shown that antigen-specific Tregs can be cultured and expanded using donor APCs such as DCs, B lymphocytes[34] and mononuclear cells. Qizhi et al[35] group estimated that 5 × 109 polyclonal Tregs would be necessary to induce tolerance when combined with 90

Conclusion

In summary, new cell immunotherapies are appearing as options for control rejection in transplantation; probably the use of Tregs seems to be most promising, although other similar cell therapies are arriving to boost this option. The promise of a durable tolerance without unwanted immuno suppression is now a clear possibility in the near future.

References

  1. Reindl-Schwaighofer R, Heinzel A, Kainz A, et al. (2019). Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort. Lancet. 393(10174):910-917. doi:10.1016/S0140-6736(18)32473-5
    View at Publisher | View at Google Scholar
  2. Bamoulid J, Staeck O, Halleck F, et al. (2015). The need for minimization strategies: Current problems of immunosuppression. Transpl Int. 28(8):891-900. doi:10.1111/tri.12553
    View at Publisher | View at Google Scholar
  3.  Povoleri GAM, Scottá C, Nova-Lamperti EA, John S, Lombardi G, et al. (2013). Thymic versus induced regulatory T cells-who regulates the regulators? Front Immunol. 4(JUN). doi:10.3389/fimmu.2013.00169
    View at Publisher | View at Google Scholar
  4. Zwang NA, Leventhal JR. (2017). Cell therapy in kidney transplantation: Focus on regulatory T cells. J Am Soc Nephrol. 28(7):1960-1972. doi:10.1681/ASN.2016111206
    View at Publisher | View at Google Scholar
  5. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, et al.(2001). Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med. 193(11):1285-1294. doi:10.1084/jem.193.11.1285
    View at Publisher | View at Google Scholar
  6.  Morgan ME, Van Bilsen JHM, Bakker AM, et al. (2005). Expression of FOXP3 mRNA is not confined to CD4 +CD25 + T regulatory cells in humans. Hum Immunol. 66(1):13-20. doi:10.1016/j.humimm.2004.05.016
    View at Publisher | View at Google Scholar
  7. Iizuka-Koga M, Nakatsukasa H, Ito M, Akanuma T, Lu Q, et al. (2017). Induction and maintenance of regulatory T cells by transcription factors and epigenetic modifications. J Autoimmun. 83:113-121. doi:10.1016/j.jaut.2017.07.002
    View at Publisher | View at Google Scholar
  8. Toker A, Engelbert D, Garg G, et al. (2013). Active Demethylation of the Foxp3 Locus Leads to the Generation of Stable Regulatory T Cells within the Thymus . J Immunol. 190(7):3180-3188. doi:10.4049/jimmunol.1203473
    View at Publisher | View at Google Scholar
  9.  Singer A, Adoro S, Park JH. (2008). Lineage fate and intense debate: Myths, models and mechanisms of CD4- versus CD8-lineage choice. Nat Rev Immunol. 8(10):788-801. doi:10.1038/nri2416
    View at Publisher | View at Google Scholar
  10.  Luo CT, Li MO. (2013). Transcriptional control of regulatory T cell development and function. Trends Immunol.;34(11):531-539. doi:10.1016/j.it.2013.08.003
    View at Publisher | View at Google Scholar
  11. Chen WJ, Jin W, Hardegen N, et al. (2003). Conversion of Peripheral CD4 + CD25 - Naive T Cells to CD4 + CD25 + Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3. J Exp Med. 198(12):1875-1886. doi:10.1084/jem.20030152
    View at Publisher | View at Google Scholar
  12. Nazzal D, Gradolatto A, Truffault F, Bismuth J, Berrih-Aknin S. (2014). Human thymus medullary epithelial cells promote regulatory T-cell generation by stimulating interleukin-2 production via ICOS ligand. Cell Death Dis. 5(9). doi:10.1038/cddis.2014.377
    View at Publisher | View at Google Scholar
  13. Lio CWJ, Hsieh CS. (2008). A Two-Step Process for Thymic Regulatory T Cell Development. Immunity. 28(1):100-111. doi:10.1016/j.immuni.2007.11.021
    View at Publisher | View at Google Scholar
  14. Delgoffe GM, Pollizzi KN, Waickman AT, et al. (2011). The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. 12(4):295-304. doi:10.1038/ni.2005
    View at Publisher | View at Google Scholar
  15. Delgoffe GM, Kole TP, Zheng Y, et al. (2009). The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment. Immunity. 30(6):832-844. doi:10.1016/j.immuni.2009.04.014
    View at Publisher | View at Google Scholar
  16.  Zeng H, Yang K, Cloer C, Neale G, Vogel P, et al. (2013). MTORC1 couples immune signals and metabolic programming to establish T reg-cell function. Nature.;499(7459):485-490. doi:10.1038/nature12297
    View at Publisher | View at Google Scholar
  17. Coenen JJA, Koenen HJPM, van Rijssen E, et al. (2007). Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+FoxP3+ T cells. Bone Marrow Transplant.39(9):537-545. doi:10.1038/sj.bmt.1705628
    View at Publisher | View at Google Scholar
  18. Demirkiran A, Hendrikx TK, Baan CC, Van Der Laan LJW. (2008). Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: Does in vitro evidence translate to the clinical setting? Transplantation. 85(6):783-789. doi:10.1097/TP.0b013e318166910b
    View at Publisher | View at Google Scholar
  19.  He X, Smeets RL, Koenen HJPM, et al. (2011). Mycophenolic acid-mediated suppression of human CD4+ T cells: More than mere guanine nucleotide deprivation. Am J Transplant. 11(3):439-449. doi:10.1111/j.1600-6143.2010.03413.x
    View at Publisher | View at Google Scholar
  20. Wu T, Zhang L, Xu K, et al. (2012). Immunosuppressive drugs on inducing Ag-specific CD4+CD25+Foxp3+ Treg cells during immune response in vivo. Transpl Immunol. 27(1):30-38. doi:10.1016/j.trim.2012.05.001
    View at Publisher | View at Google Scholar
  21. Bluestone JA, Liu W, Yabu JM, et al. (2008). The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. ;8(10):2086-2096. doi:10.1111/j.1600-6143.2008.02377.x
    View at Publisher | View at Google Scholar
  22. Boros P, Bromberg JS. (2009). Human FOXP3+ regulatory T cells in transplantation. Am J Transplant. 9(8):1719-1724. doi:10.1111/j.1600-6143.2009.02704.x
    View at Publisher | View at Google Scholar
  23. Grohmann U, Orabona C, Fallarino F, et al. (2002). CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol;3 (11):1097-1101. doi:10.1038/ni846
    View at Publisher | View at Google Scholar
  24. Akkaya B, Oya Y, Akkaya M, et al. (2019). Regulatory T cells mediate specific suppression by depleting peptide–MHC class II from dendritic cells. Nat Immunol. 20(2):218-231. doi:10.1038/s41590-018-0280-2
    View at Publisher | View at Google Scholar
  25. Martin-Moreno PL, Tripathi S, Chandraker A. (2018). Regulatory T cells and kidney transplantation. Clin J Am Soc Nephrol. 13(11):1760-1764. doi:10.2215/CJN.01750218
    View at Publisher | View at Google Scholar
  26. Bodor J, Feigenbaum L, Bodorova J, Bare C, Reitz MS, et al. (2001). Suppression of T-cell responsiveness by inducible cAMP early repressor (ICER). J Leukoc Biol. 69(6):1053-1059. doi:10.1189/jlb.69.6.1053
    View at Publisher | View at Google Scholar
  27. Tung SL, Boardman DA, Sen M, et al. (2018). Regulatory T cell-derived extracellular vesicles modify dendritic cell function. Sci Rep. 8(1). doi:10.1038/s41598-018-24531-8
    View at Publisher | View at Google Scholar
  28. Sharabi A, Tsokos MG, Ding Y, Malek TR, Klatzmann D, et al. (2018). Regulatory T cells in the treatment of disease. Nat Rev Drug Discov. 17(11):823-844. doi:10.1038/nrd.2018.148
    View at Publisher | View at Google Scholar
  29. Mizui M. (2019). Natural and modified IL-2 for the treatment of cancer and autoimmune diseases. Clin Immunol. 206:63-70. doi:10.1016/j.clim.2018.11.002
    View at Publisher | View at Google Scholar
  30.  GtR. (2019). The TWO Study: A Phase II trial of regulatory T cells in renal transplantation - can we achieve sirolimus monotherapy?.  Accessed December 10.
    View at Publisher | View at Google Scholar
  31.  Dawson NAJ, Levings MK. (2017). Antigen-specific regulatory T cells: are police CARs the answer? Transl Res.187:53-58. doi:10.1016/j.trsl.2017.06.009
    View at Publisher | View at Google Scholar
  32.  Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, et al. (2011). Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 3(83). doi:10.1126/scitranslmed.3002076
    View at Publisher | View at Google Scholar
  33.  Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C. (2011). Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 118(20):5671-5680. doi:10.1182/blood-2011-02-337097
    View at Publisher | View at Google Scholar
  34.  Chen LC, Delgado JC, Jensen PE, Chen X. (2009). Direct Expansion of Human Allospecific FoxP3 + CD4 + Regulatory T Cells with Allogeneic B Cells for Therapeutic Application . J Immunol.;183(6):4094-4102. doi:10.4049/jimmunol.0901081
    View at Publisher | View at Google Scholar
  35. Tang Q, Bluestone JA. (2013). Regulatory T-cell therapy in transplantation: Moving to the clinic. Cold Spring Harb Perspect Med. 3(11). doi:10.1101/cshperspect.a015552
    View at Publisher | View at Google Scholar
  36.  Tsang JYS, Tanriver Y, Jiang S, et al. (2008). Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest.;118(11):3619-3628. doi:10.1172/JCI33185
    View at Publisher | View at Google Scholar
  37. Hull CM, Nickolay LE, Estorninho M, et al. (2017). Generation of human islet-specific regulatory T cells by TCR gene transfer. J Autoimmun.79:63-73. doi:10.1016/j.jaut.2017.01.001
    View at Publisher | View at Google Scholar
  38.  Kim YC, Zhang AH, Su Y, et al. (2015). Engineered antigen-specific human regulatory T cells: Immunosuppression of FVIII-specific T- and B-cell responses. Blood. 125(7):1107-1115. doi:10.1182/blood-2014-04-566786
    View at Publisher | View at Google Scholar
  39. Kim YC, Zhang AH, Yoon J, et al. (2018).Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells. J Autoimmun. 92:77-86. doi:10.1016/j.jaut.2018.05.003
    View at Publisher | View at Google Scholar
  40. Brentjens RJ, Davila ML, Riviere I, et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 5(177). doi:10.1126/scitranslmed.3005930
    View at Publisher | View at Google Scholar
  41.  Davila ML, Riviere I, Wang X, et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 6(224). doi:10.1126/scitranslmed.3008226
    View at Publisher | View at Google Scholar
  42. Garfall AL, Maus M V., Hwang WT, et al. (2015). Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 373(11):1040-1047. doi:10.1056/NEJMoa1504542
    View at Publisher | View at Google Scholar
  43. Turtle CJ, Hanafi LA, Berger C, et al. (2016). Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 8(355). doi:10.1126/scitranslmed.aaf8621
    View at Publisher | View at Google Scholar
  44. Kochenderfer JN, Feldman SA, Zhao Y, et al. (2009). Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor. J Immunother. 32(7):689-702. doi:10.1097/CJI.0b013e3181ac6138
    View at Publisher | View at Google Scholar
  45. Sadelain M. (2015). CAR therapy: The CD19 paradigm. J Clin Invest. 125(9):3392-3400. doi:10.1172/JCI80010
    View at Publisher | View at Google Scholar
  46. Curran KJ, Brentjens RJ. (2015). Chimeric antigen receptor T cells for cancer immunotherapy. J Clin Oncol. 33(15):1703-1706. doi:10.1200/JCO.2014.60.3449
    View at Publisher | View at Google Scholar
  47. Chang ZNL, Chen YY. (2017). CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med. 23(5):430-450. doi:10.1016/j.molmed.2017.03.002
    View at Publisher | View at Google Scholar
  48. Raffin C, T. Vo L, Bluestone JA. (2019). Treg cell-based therapies: challenges and perspectives. Nat Rev Immunol. doi:10.1038/s41577-019-0232-6
    View at Publisher | View at Google Scholar
  49. Elinav E, Waks T, Eshhar Z. (2008). Redirection of Regulatory T Cells With Predetermined Specificity for the Treatment of Experimental Colitis in Mice. Gastroenterology. 134(7):2014-2024. doi:10.1053/j.gastro.2008.02.060
    View at Publisher | View at Google Scholar
  50. MacDonald KG, Hoeppli RE, Huang Q, et al. (2016). Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 126(4):1413-1424. doi:10.1172/JCI86827
    View at Publisher | View at Google Scholar
  51.  Boardman DA, Philippeos C, Fruhwirth GO, et al. (2017). Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am J Transplant. 17(4):931-943. doi:10.1111/ajt.14185
    View at Publisher | View at Google Scholar
  52. Noyan F, Zimmermann K, Hardtke-Wolenski M, et al. (2017).  Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor. Am J Transplant. 17(4):917-930. doi:10.1111/ajt.14175
    View at Publisher | View at Google Scholar
  53. Dawson NAJ, Lamarche C, Hoeppli RE, et al. (2019). Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells. JCI Insight. 4(6). doi:10.1172/jci.insight.123672
    View at Publisher | View at Google Scholar
  54. Passerini L, Mel ER, Sartirana C, et al. (2013). CD4+ T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer. Sci Transl Med. 5(215). doi:10.1126/scitranslmed.3007320
    View at Publisher | View at Google Scholar
  55. Beavis PA, Gregory B, Green P, et al. (2011). Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proc Natl Acad Sci U S A. 108(40):16717-16722. doi:10.1073/pnas.1112722108
    View at Publisher | View at Google Scholar
  56. Banerjee DK, Dhodapkar M V., Matayeva E, Steinman RM, Dhodapkar KM. (2006). Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 108(8):2655-2661. doi:10.1182/blood-2006-03-011353
    View at Publisher | View at Google Scholar
  57.  Hasegawa H, Matsumoto T. (2018). Mechanisms of tolerance induction by dendritic cells in vivo. Front Immunol. 9(FEB). doi:10.3389/fimmu.2018.00350
    View at Publisher | View at Google Scholar
  58. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z.  (2007). Rapamycin-Conditioned Dendritic Cells Are Poor Stimulators of Allogeneic CD4 + T Cells, but Enrich for Antigen-Specific Foxp3 + T Regulatory Cells and Promote Organ Transplant Tolerance . J Immunol. 178(11):7018-7031. doi:10.4049/jimmunol.178.11.7018
    View at Publisher | View at Google Scholar
  59. Marín E, Cuturi MC, Moreau A. (2018). Tolerogenic dendritic cells in solid organ transplantation: Where do we stand? Front Immunol. 9(FEB). doi:10.3389/fimmu.2018.00274
    View at Publisher | View at Google Scholar
  60. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ. (2009).  Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes.;58(8):1797-1806. doi:10.2337/db09-0317
    View at Publisher | View at Google Scholar
  61.  Casiraghi F, Perico N, Cortinovis M, Remuzzi G. (2016). Mesenchymal stromal cells in renal transplantation: Opportunities and challenges. Nat Rev Nephrol. 12(4):241-253. doi:10.1038/nrneph.2016.7
    View at Publisher | View at Google Scholar
  62. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O. (2013). Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: What have we learned so far. Immunol Cell Biol. 91(1):40-51. doi:10.1038/icb.2012.67
    View at Publisher | View at Google Scholar
  63. Ge W, Jiang J, Baroja ML, et al. (2009). Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 9(8):1760-1772. doi:10.1111/j.1600-6143.2009.02721.x
    View at Publisher | View at Google Scholar
  64. Zhang W, Qin C, Zhou ZM. (2007). Mesenchymal Stem Cells Modulate Immune Responses Combined With Cyclosporine in a Rat Renal Transplantation Model. Transplant Proc. 39(10):3404-3408. doi:10.1016/j.transproceed.2007.06.092
    View at Publisher | View at Google Scholar
  65. Eggenhofer E, Steinmann JF, Renner P, et al. (2011). Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol. 24(3):157-163. doi:10.1016/j.trim.2010.12.002
    View at Publisher | View at Google Scholar
  66. Gabrilovich DI. (2017). Myeloid-derived suppressor cells. Cancer Immunol Res.5(1):3-8. doi:10.1158/2326-6066.CIR-16-0297
    View at Publisher | View at Google Scholar
  67. Yang F, Li Y, Wu T, et al. (2016). TNFα-induced M-MDSCs promote transplant immune tolerance via nitric oxide. J Mol Med. 94(8):911-920. doi:10.1007/s00109-016-1398-z
    View at Publisher | View at Google Scholar
  68. Rosser EC, Mauri C. (2015). Regulatory B Cells: Origin, Phenotype, and Function. Immunity. 42(4):607-612. doi:10.1016/j.immuni.2015.04.005
    View at Publisher | View at Google Scholar
  69. Wang RX, Yu CR, Dambuza IM, et al. (2014). Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med. 20(6):633-641. doi:10.1038/nm.3554
    View at Publisher | View at Google Scholar
  70.  Lee KM, Stott RT, Zhao G, et al. (2014). TGF-β-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur J Immunol. 44(6):1728-1736. doi:10.1002/eji.201344062
    View at Publisher | View at Google Scholar
  71.  Lundy SK, Fox DA. (2009). Reduced Fas ligand-expressing splenic CD5 + B lymphocytes in severe collagen-induced arthritis. Arthritis Res Ther. 11(4). doi:10.1186/ar2795
    View at Publisher | View at Google Scholar
  72. Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, (2015). PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun.6. doi:10.1038/ncomms6997
    View at Publisher | View at Google Scholar
  73.  Peng B, Ming Y, Yang C. (2018). Regulatory B cells: The cutting edge of immune tolerance in kidney transplantation review-Article. Cell Death Dis. 9(2). doi:10.1038/s41419-017-0152-y
    View at Publisher | View at Google Scholar
  74. Pallier A, Hillion S, Danger R, et al. (2010). Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int. 78(5):503-513. doi:10.1038/ki.2010.162
    View at Publisher | View at Google Scholar
  75.  Riquelme P, Tomiuk S, Kammler A, et al. (2013).  IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther. 21(2):409-422. doi:10.1038/mt.2012.168
    View at Publisher | View at Google Scholar
  76. Hutchinson JA, Riquelme P, Sawitzki B, et al. (2011). Cutting Edge: Immunological Consequences and Trafficking of Human Regulatory Macrophages Administered to Renal Transplant Recipients. J Immunol. 187(5):2072-2078. doi:10.4049/jimmunol.1100762
    View at Publisher | View at Google Scholar

Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.

img

Virginia E. Koenig

Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.

img

Delcio G Silva Junior

Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.

img

Ziemlé Clément Méda

Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.

img

Mina Sherif Soliman Georgy

We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.

img

Layla Shojaie

The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.

img

Sing-yung Wu

Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.

img

Orlando Villarreal

Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.

img

Katarzyna Byczkowska

Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.

img

Anthony Kodzo-Grey Venyo

Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.

img

Pedro Marques Gomes

Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.

img

Bernard Terkimbi Utoo

This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.

img

Prof Sherif W Mansour

Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.

img

Hao Jiang

As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.

img

Dr Shiming Tang

Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.

img

Raed Mualem

International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.

img

Andreas Filippaios

Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.

img

Dr Suramya Dhamija

Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.

img

Bruno Chauffert

I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!

img

Baheci Selen

"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".

img

Jesus Simal-Gandara

I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.

img

Douglas Miyazaki

We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.

img

Dr Griffith

I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.

img

Dr Tong Ming Liu

I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.

img

Husain Taha Radhi

I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.

img

S Munshi

Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.

img

Tania Munoz

“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.

img

George Varvatsoulias

Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.

img

Rui Tao

Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.

img

Khurram Arshad